Add Post-Exposure Prophylaxis to Regen-COV Protocols
You'll hear buzz about using casirivimab/imdevimab (Regen-COV) to PREVENT COVID-19...especially as cases continue to rise.
You already use this monoclonal antibody combo to TREAT mild to moderate COVID-19 in outpatients age 12 or older at high risk of severe illness.
Many patients are considered at high risk, such as those with diabetes...age 65 or older...or even with a BMI over 25.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote